Ovid Therapeutics (OVID) Other Non-Current Assets (2016 - 2026)

Ovid Therapeutics has reported Other Non-Current Assets for 11 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (changed 0.0% YoY), and the FY2025 full-year result was $1.9 million, up 1998.91% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.9 million in Q1 2024, with the low at $80114.0 in Q2 2022.
• Historically, Other Non-Current Assets has averaged $1.2 million across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 88.99% — and 2025, when it surged 1998.91%.
• Ovid Therapeutics' Other Non-Current Assets stood at $261191.0 in 2022, then fell by 19.6% to $210000.0 in 2023, then sank by 56.19% to $92000.0 in 2024, then surged by 1998.91% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q2 2025), per Business Quant data.